London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting

blonca9
Nov 22, 2024
1 min read

Michael McElhaugh describes how 25% of patients overall, and 50% of patients who had low baseline levels of hepatitis B surface antigen, saw a functional cure. Given this learning, he also discusses the potential development plan going forward.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

London Healthcare Week: The CEO of Arbutus summarizes IM-PROVE I phase 2a data for imdusiran in chronic hepatitis B presented earlier this week at The Liver Meeting

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight